Switching to Second Line Treatment in Chronic GVHD : vimarsa

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

Related Keywords

Massachusetts , United States , Dana Farber Cancer Institute , Hannah Choe , Corey Cutler , Bin Chen , Mitchell Horwitz , Ohio State University , Marrow Transplant Program At Duke University , Professor Of Medicine At Harvard Medical School , Cell Therapy Program At Massachusetts , Cell Therapy Program , Massachusetts General Hospital , Harvard Medical School , Stem Cell Transplant Program , Adult Blood , Marrow Transplant Program , Duke University , Assistant Professor , Ohio State , Yi Bin Chen , Chronic Graft Versus Host Disease , Cgvhd , Steroid Refractory Disease , Partial Response To Steroid , Time To Switch , Deep Sclerotic Disease , Partial Response , Inflammatory Manifestation ,